Patent ID: 9663825
Date: 2017-05-30
CPC Classifications: A61P,C12Q,G01N

Claim:
1. A method of treating a cancer patient in need thereof with a selective histone deacetylase-6 (HDAC6) inhibitor comprising: measuring an expression level of a gene selected from the group consisting of pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (PCBD1); protein phosphatase 2, regulatory subunit B, gamma isoform (PPP2R2C); neural precursor cell expressed, developmentally downregulated 4 (NEDD4); prolyl 4-hydroxylase, alpha polypeptide II (P4HA2); SLC2A4 regulator (SLC2A4RG); sulfatase 2 (SULF2); lysosomal protein transmembrane 4 alpha (LAPTM4A); 3′-phosphoadenosine 5′-phosphosulfate synthase 2 (PAPSS2); aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase) (AKR1C1); protein tyrosine phosphatase, non-receptor type 12 (PTPN12); DCN1, defective in cullin neddylation 1, domain containing 4 ( and administering to the patient a therapeutically effective amount of a selective HDAC6 inhibitor.